Publicacions en què col·labora amb Ricardo Ruiz Villaverde (16)

2024

  1. Defining well-being in psoriasis: A Delphi consensus among healthcare professionals and patients

    Scientific Reports, Vol. 14, Núm. 1

  2. Efficacy of Risankizumab in Patients with Suboptimal Response or Failure to Ustekinumab: A Multicenter Retrospective Study in Spain

    Dermatologic Therapy, Vol. 2024

  3. Family Planning Concerns Among Women With Psoriasis: A Descriptive, Cross-Sectional, Multicenter Study

    Actas Dermo-Sifiliograficas, Vol. 115, Núm. 1, pp. 10-20

  4. Genetic polymorphisms to identify patients with an optimal response to tildrakizumab in psoriasis patients from real-life clinical practice

    Experimental Dermatology, Vol. 33, Núm. 8

  5. Pharmacogenetic biomarkers for secukinumab response in psoriasis patients in real-life clinical practice

    Journal of the European Academy of Dermatology and Venereology, Vol. 38, Núm. 9, pp. 1783-1790

  6. Real-world Safety and Efficacy of Risankizumab in Psoriatic Patients: A Multicenter, Retrospective, and Not-interventional Study

    Actas Dermo-Sifiliograficas

2023

  1. Drug Survival in Cyclosporine Treatment for Moderate to Severe Atopic Dermatitis: Analysis of the Spanish Atopic Dermatitis Registry (BIOBADATOP)

    Actas Dermo-Sifiliograficas

  2. Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group

    Journal of the European Academy of Dermatology and Venereology, Vol. 37, Núm. 12, pp. 2517-2525

  3. Treatment of severe atopic dermatitis with tralokinumab in clinical practice: short-term effectiveness and safety results

    Clinical and experimental dermatology, Vol. 48, Núm. 9, pp. 991-997

  4. [Translated article] Updated Position of the Spanish Psoriasis Group (GPs) on the Use of Biosimilar Drugs in Moderate to Severe Psoriasis

    Actas Dermo-Sifiliograficas, Vol. 114, Núm. 6, pp. T494-T501

2022

  1. Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group

    Dermatologic Therapy, Vol. 35, Núm. 2

2021

  1. A new classification of the severity of psoriasis: What’s moderate psoriasis?

    Life, Vol. 11, Núm. 7

2020

  1. The effectiveness and safety of ixekizumab in psoriasis patients under clinical practice conditions: A Spanish multicentre retrospective study

    Dermatologic Therapy, Vol. 33, Núm. 6

2018

  1. Redefining the therapeutic objective in psoriatic patients candidates for biological therapy

    Journal of Dermatological Treatment, Vol. 29, Núm. 4, pp. 334-346

2017

  1. Fiabilidad de una aplicación de ayuda a la toma de decisiones terapéuticas en el paciente con psoriasis (MDi Psoriasis®)

    Actas Dermo-Sifiliograficas, Vol. 108, Núm. 7, pp. 650-656

  2. Reliability of the MDi Psoriasis® Application to Aid Therapeutic Decision-Making in Psoriasis

    Actas Dermo-Sifiliograficas, Vol. 108, Núm. 7, pp. 650-656